About IndiTreat® test

IndiTreat® is for cancer therapy selection

With IndiTreat®, you can test different panels of drugs and drug combinations on microtumors derived from individual patients to identify resistance and sensitivity.

Key benefits of IndiTreat

  • Predict tumor resistance and sensitivity to cancer drugs
  • Select the most appropriate treatment, in accordance with guidelines or off-label
  • Improve patient quality of life through in vitro testing of drug efficacy on the individual patient
  • Identify the most effective treatment in chemo-naïve colorectal cancer patients
  • Identify the most effective treatment in late-stage colorectal cancer patients
  • Complement the genomic characterisation of tumours with functional data on resistance and sensitivity to drugs

Want to know more?

Want to know more?

Contact us

Please contact 2cureX for more information

Email: info@2cureX.com
Phone: +45 22115399
Web: www.IndiTreat.com

Upcoming events

December 7, 2021

CEO Fernando Andreu will present at ”Sedermeradagen Köbenhamn 2021” (Copenhagen, Denmark)

Read more

December 9, 2021

2cureX presents at HC Andersen Capital’s Virtual Growth Days (Copenhagen, Denmark)

Read more

January 20, 2022

2cureX present at Redeye Theme – Fight Cancer Seminar – Outlook 2022 (Stockholm, Sweden)

Read more

February 24, 2022

Year-End Report 2021

View previous reports

Key benefits of IndiTreat

  • Tumor resistance
    Predict tumor resistance and sensitivity to cancer drugs
  • Right cancer treatment
    Select the most appropriate treatment, in accordance with guidelines or off-label
  • Better patient outcome
    Improve patient quality of life through in vitro testing of drug efficacy on the individual patient
  • Help chemo-naïve CRC patients
    Identify the most effective treatment in chemo-naïve colorectal cancer patients
  • Help late-stage CRC patients
    Identify the most effective treatment in late-stage colorectal cancer patients
  • Functional precision medicine
    Complement the genomic characterisation of tumours with functional data on resistance and sensitivity to drugs